Found, a telehealth startup that treats obesity with medication and lifestyle coaching, unveiled new research showing tens of ...
Josh Gad says he's taking 'life-changing' GLP-1 medication for weight loss but admits that it can't replace having a healthy ...
Whether it is prescribed for diabetes or weight loss, Ozempic and other weight- loss drugs have found their home in Kentucky, ...
RELATED: Gynecologist Cautions Women About This "Overlooked" Ozempic Side Effect. Scientists found that Ozempic can weaken ...
Celebrating football's biggest game can bring big appetites. Buying Super Bowl fixings this year will cost about the same as ...
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...
For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...
(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).